Abstract
CD20 is a transmembrane receptor, highly expressed in more than 90% of lymphocytes. Our research aims to probe CD20 signaling pathway in the proliferation, invasion and expression of related proteins IDO/AHR. OCI-Ly3 cells were with CD20 or inhibitor rituximab, and apoptosis, cell cycle, proliferation index (PI) were detected by flow cytometry. Cell invasion and migration detection using Transwell. Western blot detection of IDO/AHR levels. Comparing to blank control group, the percentage of S in the cell cycle of the cells treated with CD20 decreased significantly, and the PI increased significantly. With the extension of the culture time, the S ratio and PI further increased significantly, the cell motility and infiltration ability were significantly enhanced, and the IDO/AHR protein level increased. Inhibition of CD20 signaling pathway (rituximab) can hamper the cells, reduce cell invasion or migration, and the protein expression of IDO/AHR in cells is significantly reduced. Correlation analysis showed that the expression of CD20 and IDO/AHR showed a negative correlation. CD20 take part in the occurrence and development of lymphoma. Its expression mainly regulates the occurrence and development of lymphoma by affecting the proliferation and invasion of lymphoma cells. Our results show that CD20 can mediate IDO/AHR and affect lymphoma. Mechanism research.
Keywords:
CD20; lymphoma; IDO/AHR
Thumbnail
Thumbnail
Thumbnail
Thumbnail
